Sanfetrinem cilexetil

Sanfetrinem cilexetil is an orally absorbable prodrug ester of sanfetrinem, a novel tricyclic β-lactam antibiotic developed by GlaxoSmithKline in the 1990s for the treatment of bacterial infections, with a primary focus on tuberculosis. As a member of the beta-lactam class (specifically, trinems/carbapenems), it acts as a cell wall synthesis inhibitor by binding to penicillin-binding proteins (PBPs) in bacteria, leading to bacterial lysis. Sanfetrinem cilexetil demonstrates broad-spectrum antibacterial activity against both gram-positive and gram-negative bacteria—including penicillin-resistant Streptococcus pneumoniae—and has shown significant efficacy in preclinical models and early clinical trials. It is currently under investigation for tuberculosis and has completed phase II trials for this indication[2][3][5][6].

Other names

sanfetrinem cilexetilGV 118819GV118819GV-118819